Literature DB >> 28120478

Potency and stability of compounded formulations of chlorambucil, melphalan and cyclophosphamide.

J H Burton1, H K Knych2, S D Stanley2, R B Rebhun1.   

Abstract

BACKGROUND: Oral chemotherapy agents are frequently compounded in veterinary medicine however, the potency of some formulations have been shown to vary from that of Food and Drug Administration (FDA)-approved products. AIMS: The objective of this study was to evaluate the potency and stability of three compounded oral chemotherapeutics commonly prescribed to be administered over time. MATERIALS &
METHODS: Compounded chlorambucil 1 mg, cyclophosphamide 5 mg and melphalan 1 mg were obtained and for potency tested upon receipt and 6 weeks later.
RESULTS: Potency ranged from 71 to 104% for chlorambucil and 58 to 109% for melphalan; 1/4 and 2/4 samples were <90% of labelled strength at baseline and 6 weeks, respectively, for both drugs. Potency of cyclophosphamide ranged from 92 to 107% with all samples +/-10% of labelled strength at all time points. DISCUSSION/
CONCLUSION: These results demonstrate variability of compounded chemotherapy products, and highlight the need to consider both potency and stability when prescribing orally compounded chemotherapy.
© 2017 John Wiley & Sons Ltd.

Entities:  

Keywords:  canine; chemotherapy; feline; oncology; veterinary

Mesh:

Substances:

Year:  2017        PMID: 28120478      PMCID: PMC5526741          DOI: 10.1111/vco.12301

Source DB:  PubMed          Journal:  Vet Comp Oncol        ISSN: 1476-5810            Impact factor:   2.613


  12 in total

1.  Pharmaceutical evaluation of compounded trilostane products.

Authors:  Audrey K Cook; Cornelia D Nieuwoudt; Susan L Longhofer
Journal:  J Am Anim Hosp Assoc       Date:  2012-05-18       Impact factor: 1.023

2.  Treatment of feline gastrointestinal small-cell lymphoma with chlorambucil and glucocorticoids.

Authors:  Timothy J Stein; Mackenzie Pellin; Howard Steinberg; Ruthanne Chun
Journal:  J Am Anim Hosp Assoc       Date:  2010 Nov-Dec       Impact factor: 1.023

3.  Accuracy and precision of compounded ciclosporin capsules and solution.

Authors:  Meghan E Umstead; Dawn M Boothe; Crisanta Cruz-Espindola; John M Macdonald; Robert Kennis; Donna Angarano
Journal:  Vet Dermatol       Date:  2012-10       Impact factor: 1.589

4.  Potency and stability of compounded cyclophosphamide: a pilot study.

Authors:  C Robat; J Budde
Journal:  Vet Comp Oncol       Date:  2016-03-30       Impact factor: 2.613

5.  Comparison of paste and suspension formulations of omeprazole in the healing of gastric ulcers in racehorses in active training.

Authors:  Jorge E Nieto; Sharon Spier; Frank S Pipers; Scott Stanley; Monica R Aleman; Donald C Smith; Jack R Snyder
Journal:  J Am Vet Med Assoc       Date:  2002-10-15       Impact factor: 1.936

6.  Treatment of chronic lymphocytic leukaemia in three dogs with melphalan and prednisolone.

Authors:  Y Fujino; S Sawamura; N Kurakawa; M Hisasue; K Masuda; K Ohno; H Tsujimoto
Journal:  J Small Anim Pract       Date:  2004-06       Impact factor: 1.522

7.  Metronomic therapy with cyclophosphamide and piroxicam effectively delays tumor recurrence in dogs with incompletely resected soft tissue sarcomas.

Authors:  R E Elmslie; P Glawe; S W Dow
Journal:  J Vet Intern Med       Date:  2008-10-03       Impact factor: 3.333

8.  Prognostic factors for multiple myeloma in the dog.

Authors:  R E Matus; C E Leifer; E G MacEwen; A I Hurvitz
Journal:  J Am Vet Med Assoc       Date:  1986-06-01       Impact factor: 1.936

9.  Frequency and Severity of Neutropenia Associated with Food and Drug Administration Approved and Compounded Formulations of Lomustine in Dogs with Cancer.

Authors:  J H Burton; S D Stanley; H K Knych; C O Rodriguez; K A Skorupski; R B Rebhun
Journal:  J Vet Intern Med       Date:  2015-12-18       Impact factor: 3.333

10.  Bioequivalence of orally administered generic, compounded, and innovator-formulated itraconazole in healthy dogs.

Authors:  D I Mawby; J C Whittemore; S Genger; M G Papich
Journal:  J Vet Intern Med       Date:  2013-11-01       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.